The incidence of adverse drug reactions (ADRs) appears to be high in patients with COVID-19, according to findings of a retrospective study published in *Clinical Pharmacology and Therapeutics*.

Data from the China Hospital Pharmacovigilance System (CHPS) were used to investigate the incidence of ADRs in 217 patients with COVID-19 who were admitted to the First Hospital of Changsha, China, between 17 January 2020 and 29 February 2020. Causality of ADRs was assessed using the WHO-Uppsala Monitoring Centre system.

ADRs were reported in 38% of patients, and were most frequently gastrointestinal disorders (23%), liver disorders (14%), skin disorders (4%) and hyperlipidaemia (1%). ADRs were attributed to use of lopinavir/ritonavir (64%), umifenovir (18%), chloroquine (5%) and antibacterials (4%), and causality was assessed as probable in 55.3% of cases and possible in 44.7% of cases. The incidence of serious ADRs was 6.4%.

Overall, 96.8% of ADRs occurred during the first 14 days of hospitalization. Multivariate regression analysis found that risk factors for ADRs included the number of drugs received during hospitalisation (odds ratio \[OR\] 3.17; 95% CI 1.60, 6.27; p=0.001), the length of stay (OR 2.02; 95% CI 1.03, 3.96; p=0.04) and underlying diseases (OR 2.07; 95% CI 1.02, 4.23; p=0.04).

\"Together, the incidence of ADRs was significantly high during the treatment period. Moreover, the active monitoring of the CHPS system reflected ADRs during COVID-19 treatment in the real world, which provided reference for safe medication in clinic,\" said the authors.
